Related Experiment Videos
Adult experience with lamotrigine
L J Willmore1, J A Messenheimer
1Department of Neurology, University of Texas Medical School, Houston 77030, USA.
Journal of Child Neurology
|January 16, 1998
Summary
Lamotrigine, an anticonvulsant, effectively reduced seizures in adults with partial epilepsy. Slow dose titration is crucial to minimize adverse events like rash, especially when combined with valproic acid.
Area of Science:
- Pharmacology
- Neurology
- Clinical Trials
Background:
- Lamotrigine is a phenyltriazine derivative with demonstrated anticonvulsant properties.
- Initial investigations focused on its efficacy in adult patients experiencing partial seizures.
Purpose of the Study:
- To evaluate the efficacy and safety of lamotrigine in adult patients with partial seizures.
- To determine optimal dosing strategies and identify potential adverse event correlations.
Main Methods:
- Placebo-controlled studies were conducted to assess responder rates, defined as a 50% or greater seizure reduction from baseline.
- Pharmacokinetic parameters such as volume of distribution and plasma protein binding were analyzed in adults.
Main Results:
- Responder rates were 20% for 300 mg/day and 36% for 500 mg/day lamotrigine.
- Adverse events were infrequent; rash occurrence was associated with rapid dose escalation and concurrent valproic acid use.
Conclusions:
- Lamotrigine demonstrates efficacy in treating partial seizures in adults.
- Slow titration is essential for safe initiation of lamotrigine therapy, particularly when co-administered with valproic acid.